Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | FABP3 | P05413 | 1/20 | 0.45 |
| ▸ | SELP | P16109 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | AKT1 | P31749 | 2/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | CDC25A | P30304 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | PRKCG | P05129 | 1/20 | 0.33 |
| ▸ | PRKCB | P05771 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | PRKCH | P24723 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157824 | 1.00 | SMN1; SMN2 (0.69) | SMN1; SMN2FABP3SELPLMNAAKT1 | |
| SCHEMBL101267 | 1.00 | SMN1; SMN2 (0.69) | SMN1; SMN2FABP3SELPLMNAAKT1 | |
| SCHEMBL8899300 | 1.00 | SMN1; SMN2 (0.69) | SMN1; SMN2FABP3SELPLMNAAKT1 | |
| SCHEMBL27168721 | 1.00 | SMN1; SMN2 (0.69) | SMN1; SMN2FABP3SELPLMNAAKT1 | |
| Glycerin SCHEMBL28844001 | 0.98 | SMN1; SMN2 (0.68) | SMN1; SMN2FABP3SELPLMNAAKT1 | |
| Glycerin SCHEMBL28844000 | 0.98 | SMN1; SMN2 (0.68) | SMN1; SMN2FABP3SELPLMNAAKT1 | |
| Choline SCHEMBL29922745 | 0.95 | SMN1; SMN2 (0.64) | SMN1; SMN2FABP3SELPLMNAAKT1 | |
| SCHEMBL14950221 | 0.90 | SMN1; SMN2 (0.57) | SMN1; SMN2FABP3SELPLMNAAKT1 | |
| SCHEMBL18471995 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2FABP3LMNAAKT1ADRA1A | |
| SCHEMBL13212932 | 0.87 | SMN1; SMN2 (0.53) | SMN1; SMN2FABP3LMNAAKT1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3706801-B1 | PLATINUM COMPLEXES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-01-14 | — | — | EP | claimed |
| EP-4646401-A1 | NOVEL IONIZABLE LIPID COMPOUNDS FOR NUCLEIC ACID DELIVERY | CELON PHARMA S.A. (PL) | 2025-11-12 | — | — | EP | claimed |
| CN-120051687-A | YaxAB nanopores, nanopore systems comprising the YaxAB nanopores and uses thereof | 韩国生命工学研究院 | 2025-05-27 | — | — | CN | claimed |
| WO-2025106806-A1 | PEGYLATED LIPIDS | Acuitas Therapeutics, Inc. (CA) | 2025-05-22 | — | — | WO | claimed |
| US-20250064768-A1 | METHODS AND COMPOSITIONS FOR TREATING AGING AND CHRONIC DISEASE | L E A F HOLDINGS GROUP LLC (US) | 2025-02-27 | — | — | US | claimed |
| CN-118178324-B | FAP alpha hydrolysis charge-turned liposome and composition, and preparation method and application thereof | 锐康九域(厦门)医药科技有限公司 | 2025-02-07 | — | — | CN | claimed |
| EP-4499052-A2 | SPHINGOLIPID-LOADED NANOBIOLOGICS FOR IMMUNE REGULATION | Icahn School of Medicine at Mount Sinai (US) | 2025-02-05 | — | — | EP | claimed |
| WO-2025024559-A1 | RNA-BASED SYNTHETIC CIRCUIT FOR PRODUCING ENGINEERED IMMUNE CELLS FOR AN EXTRACORPOREAL CELL THERAPY | STRAND THERAPEUTICS INC. (US) | 2025-01-30 | — | — | WO | claimed |
| EP-4475825-A1 | HYPERACTIVATING LIPID NANOPARTICLES | Corner Therapeutics, Inc. (US) | 2024-12-18 | — | — | EP | claimed |
| WO-2024147060-A1 | NOVEL IONIZABLE LIPID COMPOUNDS FOR NUCLEIC ACID DELIVERY | CELON PHARMA S.A. (PL) | 2024-07-11 | — | — | WO | claimed |
| US-20230270706-A1 | TRANS-CROCETIN COMPOSITIONS AND TREATMENT REGIMENS | L E A F HOLDINGS GROUP LLC (US) | 2023-08-31 | — | — | US | claimed |
| WO-2023150758-A1 | HYPERACTIVATING LIPID NANOPARTICLES | CORNER THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| US-20230210803-A1 | TRANS-CROCETIN COMPOSITIONS AND TREATMENT REGIMENS | L E A F HOLDINGS GROUP LLC (US) | 2023-07-06 | — | — | US | claimed |
| CN-116099108-A | Drug coating, drug eluting balloon catheter and preparation method thereof | 上海博脉安医疗科技有限公司 | 2023-05-12 | — | — | CN | claimed |
| WO-2023048530-A1 | ANTI-CANCER VACCINE COMPOSITION COMPRISING PEPTIDES DERIVED FROM TUMOR-ASSOCIATED ANTIGEN, AND ADJUVANT CONSISTING OF LIPOPEPTIDE AND IMMUNOACTIVE SUBSTANCE, AND USE THEREOF | 주식회사 차백신연구소 | 2023-03-30 | — | — | WO | claimed |
| EP-4111207-A1 | ACTIVITY BASED HOST CELL PROTEIN PROFILING | Regeneron Pharmaceuticals, Inc. (US) | 2023-01-04 | — | — | EP | claimed |
| EP-4096644-A1 | METHODS OF PREPARING LIPID NANOPARTICLES | Modernatx, Inc. (US) | 2022-12-07 | — | — | EP | claimed |
| EP-4025556-A1 | LIPID COMPOUND AND THE COMPOSITION THEREOF | Guangzhou Ribobio Co., Ltd (CN) | 2022-07-13 | — | — | EP | claimed |
| WO-2022132926-A1 | TISSUE-SPECIFIC NUCLEIC ACID DELIVERY BY 1,2-DIOLEOYL-3-TRIMETHYLAMMONIUM-PROPANE (DOTAP) LIPID NANOPARTICLES | OMEGA THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | claimed |
| WO-2022112855-A1 | LIPID COMPOUND AND THE COMPOSITION THEREOF | Guangzhou Ribobio Co., Ltd (CN) | 2022-06-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064768-A1 | METHODS AND COMPOSITIONS FOR TREATING AGING AND CHRONIC DISEASE | LIPC, CPT1A, CPT1B | SMN1; SMN2 260/4885FABP3 355/4885SELP 3355/4885 |
| US-20230210803-A1 | TRANS-CROCETIN COMPOSITIONS AND TREATMENT REGIMENS | TTPA, HIF1A, HIF1AN | SMN1; SMN2 160/4885FABP3 61/4885SELP 965/4885 |
| US-20230270706-A1 | TRANS-CROCETIN COMPOSITIONS AND TREATMENT REGIMENS | TTPA, HIF1A, CPT1A | SMN1; SMN2 371/4885FABP3 124/4885SELP 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.